Oxytetracycline

Oxytetracycline

SCHEMBL2614977

CN(C)C1C(O)=C(C(N)=O)C(=O)C2(O)C(O)=C3C(=O)c4c(O)cccc4C(C)(O)C3C(O)C12

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Oxytetracycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 9/20 0.70
MEN1 O00255 9/20 0.70
KMT2A Q03164 9/20 0.70
KDM4E B2RXH2 8/20 0.70
USP2 O75604 7/20 0.70
HPGD P15428 6/20 0.70
ALDH1A1 P00352 5/20 0.70
MAPT P10636 5/20 0.70
RECQL P46063 5/20 0.70
THRB P10828 4/20 0.70
POLB P06746 3/20 0.70
HIF1A Q16665 3/20 0.70
GAA P10253 1/20 0.70
HSD17B10 Q99714 5/20 0.69
L3MBTL1 Q9Y468 4/20 0.69
LMNA P02545 3/20 0.69
ALOX15 P16050 2/20 0.69
CYP2C9 P11712 1/20 0.69
BRCA1 P38398 1/20 0.69
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxytetracycline SCHEMBL2899 1.00 TDP1 (0.70) TDP1MEN1KMT2AKDM4EUSP2
Oxytetracycline SCHEMBL13782519 1.00 TDP1 (0.70) TDP1MEN1KMT2AKDM4EUSP2
Oxytetracycline SCHEMBL13782617 1.00 TDP1 (0.70) TDP1MEN1KMT2AKDM4EUSP2
Oxytetracycline SCHEMBL18048891 1.00 TDP1 (0.70) TDP1MEN1KMT2AKDM4EUSP2
Oxytetracycline SCHEMBL13782467 1.00 TDP1 (0.70) TDP1MEN1KMT2AKDM4EUSP2
Oxytetracycline SCHEMBL5507247 1.00 TDP1 (0.70) TDP1MEN1KMT2AKDM4EUSP2
Oxytetracycline SCHEMBL1292896 1.00 TDP1 (0.70) TDP1MEN1KMT2AKDM4EUSP2
Oxytetracycline SCHEMBL21133474 1.00 TDP1 (0.70) TDP1MEN1KMT2AKDM4EUSP2
Oxytetracycline SCHEMBL21133472 1.00 TDP1 (0.70) TDP1MEN1KMT2AKDM4EUSP2
Oxytetracycline SCHEMBL13782478 1.00 TDP1 (0.70) TDP1MEN1KMT2AKDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0135657-B1 ANTIBACTERIAL DRUGS AND/OR FEED CONCENTRATES EGIS GYOGYSZERGYAR (HU) 1989-12-27 EP claimed
US-20160039749-A1 11a, 12-DERIVATIVES OF TETRACYCLINE COMPOUNDS PARATEK PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-20160031802-A1 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS PARATEK PHARMACEUTICALS, INC. 2016-02-04 US disclosed
US-20160031802-A1 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS PARATEK PHARMACEUTICALS, INC. 2016-02-04 US disclosed
US-8481513-B2 3, 10, and 12a substituted tetracycline compounds PARATEK PHARMACEUTICALS, INC. (US) 2013-07-09 US disclosed
US-8481513-B2 3, 10, and 12a substituted tetracycline compounds PARATEK PHARMACEUTICALS, INC. (US) 2013-07-09 US disclosed
US-8470804-B2 11a, 12-derivatives of tetracycline compounds PARATEK PHARMACEUTICALS, INC. (US) 2013-06-25 US disclosed
US-8293931-B2 7-N-substituted phenyl tetracycline compounds TRUSTEES OF TUFTS COLLEGE (US) 2012-10-23 US disclosed
US-8168810-B2 7-phenyl-substituted tetracycline compounds TRUSTEES OF TUFTS COLLEGE (US) 2012-05-01 US disclosed
US-20120101070-A1 11a, 12-Derivatives of Tetracycline Compounds PARATEK PHARMACEUTICALS, INC. (US) 2012-04-26 US disclosed
US-20090124583-A1 7-N-substituted phenyl tetracycline compounds TRUSTEES OF TUFTS COLLEGE (US) 2009-05-14 US disclosed
US-7521437-B2 7-phenyl-substituted tetracycline compounds TRUSTEES OF TUFTS COLLEGE (US) 2009-04-21 US disclosed
US-20080306032-A1 7-Phenyl-Substituted Tetracycline Compounds PARATEK PHARMACEUTICALS, INC. 2008-12-11 US disclosed
US-20070155708-A1 e.g. 7-(4-fluorophenyl) sancycline; for treating tetracycline responsive states; antibiotic resistance; rickettsiae: pneumococci and Salmonella TRUSTEES OF TUFTS COLLEGE (US) 2007-07-05 US disclosed
US-20070155708-A1 e.g. 7-(4-fluorophenyl) sancycline; for treating tetracycline responsive states; antibiotic resistance; rickettsiae: pneumococci and Salmonella TRUSTEES OF TUFTS COLLEGE (US) 2007-07-05 US disclosed
US-20030092684-A1 Compositions and methods for treating hemorrhagic virus infections and other disorders ANTIBODY SYSTEMS, INC. 2003-05-15 US disclosed
US-20020077276-A1 Compositions and methods for treating hemorrhagic virus infections and other disorders ANTIBODY SYSTEMS, INC. 2002-06-20 US disclosed
US-5120711-A Of polymyxin B and chlorquinaldol; for treatment of mastitis or fungal infections EGIS GYOGYSZERGYAR (HU) 1992-06-09 US disclosed
US-4324799-A Fungicidal thioglycolic acid anilides, processes for their manufacture and pesticidal compositions containing them HOECHST AKTIENGESELLSCHAFT (DE) 1982-04-13 US disclosed
US-3980798-A Dichloromaleic imides for fungicidal composition and method CIBA-GEIGY CORPORATION (US) 1976-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155708-A1 e.g. 7-(4-fluorophenyl) sancycline; for treating tetracycline responsive states; antibiotic resistance; rickettsiae: pneumococci and Salmonella RAB7A, RPS7, SHPRH TDP1 3513/4885MEN1 2339/4885KMT2A 4633/4885
US-20020077276-A1 Compositions and methods for treating hemorrhagic virus infections and other disorders IL1R1, TNF, IL1A TDP1 1636/4885MEN1 2311/4885KMT2A 3996/4885
US-20090124583-A1 7-N-substituted phenyl tetracycline compounds HDAC7, CASP7, CYP3A7 TDP1 1320/4885MEN1 3102/4885KMT2A 2846/4885
US-20030092684-A1 Compositions and methods for treating hemorrhagic virus infections and other disorders CCL11, SSB, TNF TDP1 1126/4885MEN1 2687/4885KMT2A 3218/4885
US-20080306032-A1 7-Phenyl-Substituted Tetracycline Compounds TCF7, TPR, CYP3A7 TDP1 1835/4885MEN1 3188/4885KMT2A 2608/4885
US-20120101070-A1 11a, 12-Derivatives of Tetracycline Compounds TOP2A, DHFR, TET1 TDP1 1441/4885MEN1 2527/4885KMT2A 1883/4885
US-20160031802-A1 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS MYC, TET3, MYCBP TDP1 3702/4885MEN1 1030/4885KMT2A 796/4885
US-20160039749-A1 11a, 12-DERIVATIVES OF TETRACYCLINE COMPOUNDS TOP2A, DHFR, TET1 TDP1 1441/4885MEN1 2527/4885KMT2A 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.